

Karolinska Development AGM 2022: Information on candidates nominated for election to the board (re election)

Björn Cochlovius

Board member since 2020 and Chairman since 2020.

Born 1968. Doctorate (Dr.rer.nat) from Universität des Saarlandes und Habilitation, Assoc. Prof Universität Heidelberg.

Other assignments: CEO Medraxe Therapeutics GmbH, Chairman of the Board of Directors of Sapreme Technologies BV, SVP Business Development at Atriva Therapeutics GmbH, President at Biocure Technologies Ltd and General Manager at BC BioMed Consulting GmbH.

Prior assignments include i.a.: Chairman of the Board of Isogencia Ltd, Senior Director Development Asia-Pacific at Abbvie Inc., Head Oncology at Otsuka, co-founder and Interim-CEO and Chairman of the Board of Ciliatech AG, Director Business Development Oncology at Roche AG, strategy consultant at Alpharma AS (nowadays Axellia), CEO at OnTarget Neurology AS, Head R&D at Affitech AS.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

No holdings in Karolinska Development.

Theresa Tse

Board Member since 2017.

Born 1992. Bachelor's Degree of Science in Economics from the Wharton School of University of Pennsylvania.

Other appointments: Chairwoman of the Board and Executive Director of Sino Biopharmaceutical Ltd (listed at the Hong Kong stock exchange) and member of the Board of Directors of invoX Pharma Ltd., France Investment (China 1) Group Limited, Chia Tai Life Technology Limited and Yun On Investment Holding Limited.

Independent of the company and its executive management. Not independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 128,736,384 shares (by related legal person).

Anna Lefevre Skjöldebrand

Board Member since 2021.

Born 1969. Masters of Law from Uppsala University.

Other appointments: CEO Swedish Medtech Service AB. Current board assignments include: Sweden Medtech4Health AB (Chairwoman), Swecare, St Eriks ögonsjukhus and COCIR, Life Science office of Sweden.

Prior assignments include i.a.: Head of Legal Swedish Medtech Service AB, Advokat Delphi & Co, Advokat GLS Legal, Jurist Ernst & Young Law, Legal Counsel Front Capital Systems AB. Previous board

assignments include i.a.: Dedicare AB, E-hälsomyndigheten, SIS AB and Medtech Europe. She has also been a member of the board in the Board for Public Procurement.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

No holdings in Karolinska Development.

Ben Toogood

Board Member since 2021.

Born 1976. Bachelor of Pharmacy from Rhodes University. MSc. from University of Witwatersrand and Executive MBA from University of Cambridge.

Other appointments: Head Global Business Development, Sino Biopharmaceuticals Limited, director of invoX Pharma Limited, Softhale BV and pHion Therapeutics.

Previous assignments include i.a.: Head Global BD & M&A Sandoz AG, Group New Business Development Executive Aspen Pharmacare Holdings, Vice President Global Business Development Pharmathen SA, International Licensing Executive Niche Generics (Unichem Laboratories) and Regulatory Affairs Merck Generics (Mylan).

Independent of the company and its executive management. Not independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 64,001 shares.

Philip Doung

Board Member since 2022.

Born 1990. Bachelor's degree of Commerce from University of Toronto.

Other appointments: Head of Investments at Sino Biopharmaceuticals Limited, member of the Board of Directors at Softhale BV and Treadwell Therapeutics.

Previous assignments include i.a.: Vice President at Deutsche Bank AG (Hong Kong Branch).

Independent of the company and its executive management. Not independent in relation to the company's major shareholders.

No holdings in Karolinska Development.